Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Melanoma 37Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Neoplasms 9Colorectal Neoplasms 9Thyroid Carcinoma, Anaplastic 8Neoplasm Metastasis 6Multiple Myeloma 5Glioma 5Pancreatic Neoplasms 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Recurrence 3Prostatic Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Hematologic Neoplasms 3Ameloblastoma 3Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibroma, Plexiform 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Breast Neoplasms 2Astrocytoma 2

Interventions

Cyclophosphamide 184fludarabine phosphate 162fludarabine 128Busulfan 116Tacrolimus 109Mycophenolic Acid 101Whole-Body Irradiation 97Antilymphocyte Serum 87Peripheral Blood Stem Cell Transplantation 84Azacitidine 82Melphalan 81Filgrastim 74Cytarabine 74Cyclosporine 72Methotrexate 64Decitabine 57Granulocyte Colony-Stimulating Factor 51Thiotepa 45Radiotherapy 41thymoglobulin 40Stem Cell Transplantation 40Cord Blood Stem Cell Transplantation 40venetoclax 39Clofarabine 35Sirolimus 30Methylprednisolone 30Specimen Handling 27Etoposide 24Alemtuzumab 24Biopsy 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Myelodysplastic Syndromes × trametinib × Clear all
NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
21 enrolled 14 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡